News of Note—GlaxoSmithKline’s Mosquirix, Emergent BioSolutions and more

In this week's news of note, a pilot study of GSK’s malaria vaccine, Mosquirix, has been delayed. (Pixabay)

Here is some other vaccine news of note for the week:

> Stakeholders are still navigating the complex planning process for a three-country pilot study of GlaxoSmithKline’s Mosquirix. Financial Times article

> Emergent BioSolutions got approval to introduce its anthrax vaccine, BioThrax, in Italy, Poland, the U.K., the Netherlands and France. Washington Business Journal article

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> CDC Director Robert Redfield divested stock in Baltimore vaccine company Profectus BioSciences before taking on the CDC job. The Washington Post article

Suggested Articles

Sanofi lost an appeal challenging the ban on its dengue vaccine Dengvaxia in the Philippines, despite an ongoing outbreak there.

After countless headlines from a Dengvaxia safety scandal in the Philippines, officials are now considering using the Sanofi vaccine again.

Merck's oncology superstar Keytruda has been stealing the spotlight, but in vaccines, the drugmaker has growth figures to tout.